Metrics cut 2
- FY27 EBITDA guidance cut to ₹220-230 crore (from ₹250-280 crore)
- FY27 vanillin production cut to ~3,000 tons (from 3,600-4,000 tons)
Event Participants
Executives
3 Ashish Dandekar, Nirmal Momaya, Santosh Parab
Analysts
8 Archit Singhal, Avnish Tiwari, Navish, Niraj, Rehan, Satish Kumar, Surya Narayan Patra, Vvinit Gada
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹5,199 million | +28% YoY, +~₹1,000 million QoQ; strong volume growth across all segments |
| EBITDA Margin | 4% | Down sharply QoQ; 4-5% gross margin loss from geopolitical raw material inflation (3-4%) and dealer financing costs (1-2%) |
| Specialty Ingredients Revenue | ₹4,000+ million | Includes blends of ₹3,000+ million; 20%+ growth run rate vs. 25-30% budget; EBITDA margin 6.35% |
| Aroma (Vanillin) Sales | ~560 tons | Primarily ethyl vanillin; negative EBITDA ~₹4 crore on ~25% capacity utilization (400 tons produced vs. 6,000 tpa capacity) |
| Performance Chemicals Revenue | ₹1,750 million | Includes ₹1,300 million inter-segment transfers; external sales ~₹400 million; EBITDA negative in Q1 due to diphenol plant shutdown |
| Gross Debt | ₹640 crore | Down from ₹670 crore (Mar-26) via IFC/EXIM loan prepayments; no new debt in Q1 |
| Vanillin Realizations | $13-14/kg | Stable in US/Europe; capacity ramp-up is key to margin recovery |
| Working Capital Cycle | ~100 days | Elongated due to Red Sea/Hormuz rerouting via South Africa and slower customer recoveries |
Geographic & Segment Commentary
Specialty Ingredients (Blends & Sales): Revenue exceeded ₹4,000 million with 20%+ growth. EBITDA margin at 6.35% vs. normalized 10%+; Q1 lost 4-5% gross margin from raw material pass-through lag (3-4%) and dealer financing costs (1-2%). Brazil fire caused air freight at high prices (₹8 crore negative in Q1, normalizing in Q2). Mature markets (US, Mexico) delivered 14% EBITDA vs. normal 17%. Management expects Q2 margins to recover as landed material replaces air freight and partial price increases are passed.
Aroma (Vanillin): Sold ~560 tons in Q1 (ethyl vanillin-led, plus 350 tons of methyl vanillin from channel stock). Production at only ~400 tons due to cautious ramp-up; 95% customer approval achieved for ethyl vanillin in first shot. Fixed cost of ₹7 crore/month at 6,000 tpa capacity created negative EBITDA (₹4 crore). Switch to methyl vanillin campaign (lower cost, higher margin) from mid-August; Q2 guidance of 500-600 tons with positive EBITDA. FY27 production guided at ~3,000 tons (4 campaigns/year, ~1 month lost per switch).
Performance Chemicals: Total revenue ₹1,750 million, of which ₹1,300 million is inter-segment transfers to Specialty Ingredients (states) and Aroma (guaiacol). Diphenol plant remains shut on uneconomical phenol prices; intermediates procured from China at competitive rates (secured for 2 quarters). External sales of ~₹400 million (catechol, HQE, TBC); catechol external sales stopped to support internal needs. EBITDA negative in Q1, expected positive from Q2 as selling catechol at a loss ceases. Decision on alternate plant use (phenolic compounds) by Q3.
Company-Specific & Strategic Commentary
New segmental disclosure: Business now reported in 3 verticals — Specialty Ingredients, Aroma, and Performance Chemicals — with inter-segment transfers on arm's-length basis. Reporting switched to INR millions for international comparability.
Ethyl vanillin scale-up: 750 MT campaign half-completed in Q1; 95% customer approval achieved. Post-August switchback to methyl vanillin, where raw materials are acquired at competitive prices, yielding better gross margins; ethyl vanillin next run expected to match methyl margin profile as costs rationalize.
Diphenol plant strategy: Shutdown continues on high phenol/raw material prices. Management evaluating alternate products (phenolic compounds) with decision by Q3; Chinese intermediates secured for 2 quarters; HQE and TBC internal/external sales increasing to partially offset.
Brazil fire settlement: Insurance claim of ₹400 million settled at 20% haircut to accelerate cash; one-time exceptional item recorded in Q1; air-freight disruption impact of ₹8 crore expected to reverse in Q2.
Capital management: Exploring credit lines of ₹100-200 crore within 1-1.5 months; capital raise options under evaluation tied to market conditions and ratings. Using supplier/dealer financing (1-1.5% margin impact) to bridge working capital gaps.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue (FY27) | ₹2,200-2,300 crore | Top line "very, very secured"; earlier ₹2,000-2,400 crore range maintained |
| EBITDA Margin (FY27) | 10-11% | Revised down from earlier ₹250-280 crore EBITDA guidance; implies ₹220-230 crore EBITDA |
| H2 FY27 EBITDA Margin | 13-15% | Q2 sequential improvement across all segments; Q3 ~double-digit company-level margin |
| Q2 FY27 Vanillin Volumes | 500-600 tons | Methyl vanillin campaign with better margins; Aroma EBITDA positive from Q2 |
| FY28 Normalized EBITDA Margin | 12-14% | Assumes raw material prices stabilize; Q3 FY27 closest to normalized margins |
| Additional Credit Lines | ₹100-200 crore | Expected in place within 1-1.5 months; tied to working capital needs as revenue scales |
| FY27 Vanillin Production | ~3,000 tons | Down from earlier 3,600-4,000 tons due to slow ethyl ramp-up and campaign switches (4 months lost) |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical conflict prolongation | Elevated raw material prices and freight (Red Sea/Hormuz rerouting via South Africa) expected to persist at least through Q2; 3-4% gross margin compression from raw material pass-through lag continues. Management assumes elevated prices for at least 3 months. |
| Working capital/liquidity pressure | ~100-day cycle with elongated customer recoveries from global slowdown; additional ₹100-200 crore funding likely. Dealer financing adds 1-1.5% to costs; management evaluating credit lines and capital raise options. |
| Diphenol plant indefinite shutdown | Idle capacity due to uneconomical phenol prices; decision on alternate use (phenolic compounds) by Q3. Sourcing Chinese intermediates for 2 quarters creates supply concentration risk; external Performance Chemical sales exposed. |
| Vanillin ramp-up execution | 4 campaigns/year costs ~1 month production each; FY27 production at ~3,000 tons vs. 6,000 tpa capacity limits fixed cost absorption. Slower ramp dilutes quarterly margins until utilization crosses ~60-70%. |
| Price discipline vs. Solvay | Market leader holds US/Europe prices at $13-14 to prevent Chinese re-entry despite 250% ADD (at $20, Chinese landed cost becomes competitive); limits pricing upside even as 5,000-6,000 ton supply gap exists in US/Europe. |
| Liquidation entities | China in liquidation process with ₹10-20 million expenditure expected this quarter; Europe liquidation winding down with minimal ongoing cash burn. |
Q&A Highlights
FY27 Guidance Deliverability
- Question: With Q1 EBITDA at ~₹9 crore, is the ₹220-230 crore EBITDA target deliverable? (Avnish Tiwari, Vaikarya)
- Answer: Yes, within reach given current cost structure. Q2 raw material pressure remains but price pass-through is in progress; 10% EBITDA over the next 9 months is on target. FY28 normalized margin of 12-14% achievable. (Santosh Parab)
Debt and Balance Sheet
- Question: What is the debt level and deleveraging plan? (Avnish Tiwari)
- Answer: Gross debt at ₹640 crore, down from ₹670 crore at March-end on prepayments of IFC/EXIM loans for the vanillin plant. No net debt increase in Q1 despite revenue growth; managed via dealer financing (adding 1-1.5% to costs) and supplier/dealer channels. May need ₹100-200 crore credit lines as revenue scales to ₹2,400 crore. Capital raise options being evaluated on market conditions, rating, and interest rates. (Santosh Parab)
Vanillin EBITDA Loss Explained
- Question: Why loss despite $13-14 realizations versus $9-10 cost per kg? (Rehan, Coheron Wealth)
- Answer: Capacity utilization is the key — only ~400 tons produced in Q1 vs. 6,000 tpa capacity; ₹7 crore/month fixed cost cannot be absorbed at ~25% utilization. At 60-70% utilization (3,000 tons/year), 7% EBITDA achievable at $13 prices. This quarter's loss is a quarterly accounting cut-off artifact. (Santosh Parab)
Blends Margin Softening & Q2 Outlook
- Question: Why haven't blends margins recovered to 14-15% levels? (Rehan)
- Answer: Q1 lost 4-5% gross margin: 3-4% from geopolitical/raw material pass-through lag and 1-2% from dealer financing. Brazil fire added ₹8 crore negative from air-freighting material; that gets corrected in Q2 as shipped stock lands. Some price increases already passed. All three segments will be significantly better in Q2 vs. Q1; Q3 is closest to normalized. (Nirmal Momaya)
Double-Digit Margin Timing
- Question: When will company-level EBITDA reach double-digit margins? (Rehan)
- Answer: Q3 FY27. (Nirmal Momaya)
Segment Growth Discrepancy
- Question: Why do segmental growth rates exceed 30% while blended company growth is ~22-23%? (Surya Narayan Patra, PhillipCapital)
- Answer: Different price-volume mix versus year-ago quarter. States business is saturating; Aroma is growing with better post-ADD realizations; Performance Chemical sells leftovers after internal consumption (less catechol/hydroquinone available externally when downstream sells well). (Santosh Parab)
Diphenol Shutdown Impact
- Question: What happens if shutdown continues? (Surya Narayan Patra)
- Answer: Performance Chemical's ₹1,750 million revenue includes ₹1,300 million inter-segment transfers; external sales are only ~₹400 million. Catechol external sales stopped entirely; HQE and TBC sales increasing. Decision on alternate product use (phenolic compounds) by Q3; options being evaluated for best margin and returns. (Nirmal Momaya)
FY27 Vanillin Volume Cut
- Question: Why reduce from 3,600-4,000 tons to ~3,000 tons? (Navish, Burman Capital)
- Answer: Ethyl vanillin ramp-up took longer than anticipated — deliberately cautious to achieve quality standards; 95% customer approval in first shot. Each campaign switch costs ~1 month of production; 4 campaigns expected this year = 4 months lost. FY28 can scale to ~5,000 tons with optimized campaign planning and production of 400-500 tons/month. (Nirmal Momaya)
Working Capital and Credit Lines
- Question: Working capital requirement and timing of funding? (Vvinit Gada, Sanghvi Family Office)
- Answer: Consolidated working capital cycle at ~100 days; ₹1 crore of revenue requires ~₹0.33 crore of working capital support. Additional credit lines of ₹100-150 crore expected to be in place within 1-1.5 months. (Santosh Parab)
Normalized EBITDA If Normal Quarter
- Question: What would EBITDA have been in a normal environment? (Satish Kumar, InCred Equities)
- Answer: At least 6% more — EBITDA would have been in the ₹37-40 crore range vs. ~₹9 crore actual. The 4-5% gross margin loss travels directly to EBITDA. (Nirmal Momaya, Santosh Parab, Ashish Dandekar)
Vanillin Price Discipline & Supply Gap
- Question: Why aren't US/Europe prices rising despite the supply gap? (Niraj, White Pine Investment Management)
- Answer: Channel inventory is now cleared; a 5,000-6,000 ton supply gap exists in US/Europe. However, Solvay (market leader) holds prices at $13-14 — if they raise to $20, Chinese suppliers re-enter even with 250% ADD (landed cost ~$8-8.50). Solvay also protects global pricing relationships with multinational F&F customers buying at $8 elsewhere. (Nirmal Momaya, Santosh Parab)
Key Takeaway
Camlin Fine Sciences posted strong top-line growth in Q1 FY27 with revenue of ₹5,199 million (+28% YoY), but EBITDA margin compressed to 4% from a 4-5% gross margin loss driven by geopolitical raw material inflation, freight rerouting via South Africa, and dealer financing costs. Specialty Ingredients grew 20%+ (₹4,000+ million, 6.35% EBITDA margin); Aroma sold 560 tons of vanillin at 25% capacity utilization (negative ~₹4 crore EBITDA); Performance Chemicals remained negative with the diphenol plant shut. Management revised FY27 guidance to ₹2,200-2,300 crore revenue with 10-11% EBITDA margins (₹220-230 crore), expecting Q2 sequential improvement across all segments and double-digit company-level margins from Q3. Gross debt held at ₹640 crore; ₹100-200 crore of credit lines are being arranged. Key watch items: raw material price persistence, vanillin ramp-up (3,000 tons for FY27 vs. 6,000 tpa capacity), and the diphenol plant's alternate-use decision due by Q3.